The 7 most recent market catalysts affecting $DARE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 55
Daré Bioscience Announces $908K NIH Award For Preclinical Development Of DARE-PTB2 In Preterm Birth Prevention, With Recommended Future-Year Support Of About $1.3M
This NIH award is a positive development for Daré Bioscience, providing non-dilutive capital for the preclinical development of DARE-PTB2. This extends the company's cash runway an…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 55
Dare Bioscience Files Prospectus Related To The Resale Of Up To 8,934,345 Shares Of Common Stock By Selling Stockholders
Dare Bioscience has filed a prospectus to register for resale up to 8,934,345 shares of common stock held by various selling stockholders. This action is a standard procedure follo…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 65
Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure
Dare Bioscience (DARE) has announced the publication of Phase 1 clinical study results for its proprietary Sildenafil Cream, 3.6%, in a peer-reviewed journal. The study demonstrate…
Aug 14, 2026
Market Technicals
Bullish
Impact 75
Dare Bioscience Shares Halted On Circuit Breaker To The Downside, Stock Now Up -16.79%
The circuit breaker halt for Dare Bioscience (DARE) shares is a direct consequence of extreme price volatility, specifically a rapid decline. This event signals strong negative sen…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 75
Daré Bioscience Announces $6M Offering Of 4,379,581 Shares (Or Pre-Funded Warrants To Purchase Shares Of Common Stock In Lieu Thereof) At $1.37/Share
Daré Bioscience is conducting a registered direct offering and a concurrent private placement to raise $6 million. This involves issuing new shares and warrants, which will dilute …
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 65
Dare Bioscience shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline represents a direct corporate catalyst, as Dare Bioscience's stock is reacting positively to its own strong financial performance. The impact is moderate because whil…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 92
Dare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K Estimate
Dare Bioscience's Q2 earnings report shows a substantial beat on both EPS and sales estimates. The company's reported loss of $(0.20) per share was better than the $(0.24) consensu…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.